Early access
Sign in
Taking people in United StatesNo phase

Survey of treatment preferences among adults with primary immune thrombocytopenia

Asks adults with primary immune thrombocytopenia in the US what they prefer in treatment.

Key facts

Who runs it
Novartis Pharmaceuticals
Where
East Hanover, United StatesSee the site
Trial code
Registry title
A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
Status
Recruiting
People taking part
100 people, planned
Started
8 Dec 2025
Expected to end
15 Dec 2026
Type of study
Observational
Record updated
1 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in the US with primary immune thrombocytopenia (ITP), a low blood platelet condition. They answer a survey about which treatments they prefer.

Age
18 years and older
Sex
All sexes
Disease stage
Primary ITP, treated with first-line (1L) or second-line (2L) treatment.
Earlier treatment
1L group: started 1L corticosteroids within 3 months of diagnosis and responded to them, with or without IVIg. 2L group: needs or takes TPO-RA treatment after 1L corticosteroids (with or without IVIg) did not work well enough or the disease came back.

Main reasons for not taking part

  • Not living in the US
  • 1L group: past or current use of treatments other than corticosteroids and/or IVIg/anti-D immunoglobulin
  • 2L group: past or current use of treatments other than corticosteroids, IVIg/anti-D immunoglobulin or one TPO-RA
  • Any treatment used as third-line treatment

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Currently living in the US
  • Aged 18 years and older on the day of providing informed consent
  • A diagnosis of primary ITP:; For participants receiving first-line (1L) treatment for ITP: i. Diagnosed with primary ITP and started 1L corticosteroids within 3 months of diagnosis ii. Responded to 1L corticosteroid treatment [with or without intravenous immunoglobulin (IVIg)] b. For participants receiving second-line (2L) treatment for ITP: i. Assessed as needing or are taking thrombopoietin receptor agonist (TPO-RA) treatment for 2L treatment ii. Has previously been treated with a 1L corticosteroid (with or without IVIg) with insufficient response or relapse

Who cannot take part

  • For participants receiving 1L treatment for ITP only: Previous or current use of treatments different from corticosteroids and/or IVIg/anti-D immunoglobulin
  • For participants receiving 2L ITP treatment: Previous or current use of treatments different from corticosteroids, IVIg/anti-D immunoglobulin or one TPO-RA (i.e. patients who have used any treatment in a third-line setting are ineligible)

Where in United States

  • NovartisEast Hanover, United StatesContact: Novartis PharmaceuticalsTaking people

About the trial

What the trial wants to find out

This study aims to evaluate treatment preferences of patients with Primary Immune Thrombocytopenia (ITP) in the United States (US) by conducting a preference elicitation survey.

The group in the trial

  • ITP Cohort

    Adults with ITP in the US who are being treated in either 1L or 2L settings.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Patients' Preferences for Primary Immune Thrombocytopenia Treatment
Plain-language title
Survey of treatment preferences among adults with primary immune thrombocytopeniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
1 October 2026